GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells ...

Leave no stone unturned. This is a basic tenet of any investigation, something I learned very early in my career as a special agent. It also seems to be a practice employed by my healthcare team, ...